Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Parrott

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 30, 2021
Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 EnzymesRyan H Takahashi, William F Forrest, Alexander D Smith, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
Journal of Clinical Pharmacology|December 28, 2019
Coexpression of Human Hepatic Uridine Diphosphate Glucuronosyltransferase Proteins: Implications for Ontogenetic Mechanisms and Isoform CoregulationYuejian Liu, Justine Badée, Ryan H Takahashi, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 8, 2021
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-MakingNassim Djebli, Vincent Buchheit, Neil Parrott, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 21, 2015
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humansKelli J Glenn, Li J Yu, Micaela B Reddy, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
Transplantation Direct|August 9, 2016
Well, I Wouldn't be Any Worse Off, Would I, Than I am Now? A Qualitative Study of Decision-Making, Hopes, and Realities of Adults With Type 1 Diabetes Undergoing Islet Cell TransplantationJane Speight, Alison J Woodcock, Matthew D Reaney, et al.
Lab on a Chip|February 2, 2022
Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studiesLuca Docci, Nicolò Milani, Thomas Ramp, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy SubjectsPeter N Morcos, Neil Parrott, Ludger Banken, et al.
The AAPS Journal|March 10, 2026
PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation DevelopmentGilbert J Burckart, Susan Abdel-Rahman, Caleb Choi, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 30, 2021
Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 EnzymesRyan H Takahashi, William F Forrest, Alexander D Smith, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
Journal of Clinical Pharmacology|December 28, 2019
Coexpression of Human Hepatic Uridine Diphosphate Glucuronosyltransferase Proteins: Implications for Ontogenetic Mechanisms and Isoform CoregulationYuejian Liu, Justine Badée, Ryan H Takahashi, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 8, 2021
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-MakingNassim Djebli, Vincent Buchheit, Neil Parrott, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 21, 2015
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humansKelli J Glenn, Li J Yu, Micaela B Reddy, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
Transplantation Direct|August 9, 2016
Well, I Wouldn't be Any Worse Off, Would I, Than I am Now? A Qualitative Study of Decision-Making, Hopes, and Realities of Adults With Type 1 Diabetes Undergoing Islet Cell TransplantationJane Speight, Alison J Woodcock, Matthew D Reaney, et al.
Lab on a Chip|February 2, 2022
Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studiesLuca Docci, Nicolò Milani, Thomas Ramp, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy SubjectsPeter N Morcos, Neil Parrott, Ludger Banken, et al.
The AAPS Journal|March 10, 2026
PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation DevelopmentGilbert J Burckart, Susan Abdel-Rahman, Caleb Choi, et al.
Pageof 13